Peptide receptor radionuclide therapy (PRRT) with Lu-DOTATATE following liver directed therapy (LDT) in neuroendocrine tumors (NETs): Hepatotoxicity and impact on progression-free survival (PFS)

#3172

Introduction: PRRT (Lu-DOTATATE) and LDT (e.g. hepatic artery embolization) are commonly used in treating liver dominant NETs. Hepatotoxicity from PRRT in the setting of metastatic disease and prior liver-directed therapy is an important consideration. There is a concern for hepatotoxicity in patients receiving PRRT based on the literature, but there is limited data on patients who may have had a prior liver injury from LDT.

Aim(s): To compare hepatotoxicity and PFS in patients receiving PRRT in the presence or absence of prior treatment with LDT

Materials and methods: We retrospectively divided patients who received PRRT between September 2018 and October 2019 into two groups according to their prior history of LDT. LDT was defined as hepatic artery embolization, radio-embolization, or image-guided thermal ablation. Liver chemistries (albumin, bilirubin, ALT, AST, ALP) were obtained before the first PRRT cycle and 2 months after their last cycle. PFS was determined from their last follow-up imaging. Kaplan-Meier and t-paired test were used

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Badawy M

Authors: Badawy M, Halfdanarson T, Johnson G, Hobday T, Young J,

Keywords: hepatotoxicity, PRRT (LU-DOTATATE), liver targeted therapy, progression-free survival, NEN, NET,